-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 25, 2021, CDE data showed that the ivabradine hydrochloride tablets (National Medicines Standard H20213404) declared by Beijing Baiao Pharmaceutical Co.
According to the "China Cardiovascular Disease Report 2018" data, cardiovascular disease is the leading cause of death for Chinese residents.
The mortality and rehospitalization rates of patients with heart failure within 2 to 3 months after discharge are as high as 15% and 30%.
Ivabradine was originally made into tablets in the form of hydrochloride.
The so-called essential medicine is a concept put forward by the World Health Organization (WHO) in 1977.
On March 1, 2021, the National Health Commission convened the 2021 National Pharmaceutical Administration Video and Telephone Conference.
At present, only ivabradine hydrochloride tablets from the original research manufacturer Servier are on the market in China.
At the same time, data from Meinenet showed that the sales of ivabradine hydrochloride tablets in China's public medical institutions increased by 705.
